Prostate Cancer Research Highlights

Prostate cancer screening dropped from 2019, before the start of the COVID-19 pandemic, to the second year in 2021, and numbers still hadn't rebounded by 2023.

ACS Professor Dr. Chinnaiyan led the development of a new urine test to identify whether a man has a high-grade prostate cancer.

Five years after guidelines recommended against routine prostate cancer screening, later stage cancers continue to increase—for unknown reasons.

ACS grantee's discovery of two new pathways to the well-known protein target, EZH2, may lead to new treatments for prostate cancer.

Researchers urge insurance providers to cover proton beam therapy in prostate cancer clinical trials to gain more evidence and reduce racial disparities in care.

Study finds that US states that expanded Medicaid still have barriers to adequate care from specialists for men with prostate cancer.

Study finds that developing obesity after treatment was linked with an increased risk of death from prostate cancer for all men regardless of race.

Study finds that enhancing certain immune cells’ toxicity in bone may present a new treatment option for bone metastatic prostate cancer.

An American Cancer Society research grantee found that a drug for chest pain can block the growth of prostate cancer in mice by blocking fat metabolism.

Data from the ACS CPS-II Nutrition Study help show that prostate cancer survivors who eat more chicken and less steak may live longer.

Using CPS II data, researchers found that after a prostate cancer diagnosis, men with obesity or who gain 10 lbs, are more likely to die from all causes.

The development of a new predictive tool, using genetic information, may help guide treatment for prostate cancer, especially for African-American men.